Atlas Trials

A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)

Clinical trial NCT06436742 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06436742
Sponsor
argenx
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Congenital Myasthenic SyndromeCMS
Start date
2024-09-24
Primary completion
2027-08-24
Enrollment
15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.